We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Combination of Gene Mutations Linked to Endometrial Cancer

By LabMedica International staff writers
Posted on 21 Aug 2019
The endometrium is the dynamic inner layer of the uterus, composed of stroma and epithelial cells that undergo monthly proliferation, differentiation, and shedding throughout the menstrual cycle in reproductive age women.

An estimated 63,230 women will be diagnosed with endometrial cancer (EC) this year. More...
Disruption of normal endometrial processes results in a number of pathologies, including endometrial hyperplasia, EC, endometriosis, adenomyosis, and endometriosis-associated ovarian cancer (EAOC).

Gynecologists and their colleagues at Michigan State University (Grand Rapids, MI, USA) identified a combination of two gene mutations that are linked to endometrial cancer. They found that mutations of the AT-Rich Interaction Domain 1A (ARID1A) and the Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform (PIK3CA) genes are frequently found together in the development of EC, as well as in EAOC. The team analyzed the samples with a next-generation sequencer, the NextSeq 500, a machine that rapidly sequences the human genome.

ARID1A is a tumor suppressor. When it mutates, chromatin, cellular material that keeps DNA compacted in cells, loses its structure, allowing cancer to spread. PIK3CA is an instructional gene that tells the body to produce certain proteins and leads to uncontrolled growth of cells when it mutates. Similarly, these same mutations often are found in women who have endometriosis, a painful condition in which uterine tissue grows outside the uterus, but many of those affected never develop endometrial cancer.

Ronald L. Chandler, PhD, an assistant professor of obstetrics, gynecology and reproductive biology, and corresponding author of the study, said, “We're trying to understand why some women with the same set of mutations get cancer and some don't. There is something else involved. The hardest part of our job is figuring out what's causing it. Is it something in the environment or it is something else? It's a complex process. These are big questions that we're trying to address.” The study was published on August 7, 2019, in the journal Nature Communications.

Related Links:
Michigan State University


Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Parainfluenza Virus Test
PARAINFLUENZA ELISA
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.